SAVA NASDAQ
Cassava Sciences, Inc.
1W: -11.3%
1M: -4.4%
3M: -38.8%
YTD: -6.2%
1Y: -26.6%
3Y: -47.9%
5Y: -69.1%
$1.96
Last traded 2026-03-16 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$0.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$94.4M
52W Range1.15-4.98
Volume258,479
Avg Volume857,770
Beta-0.84
Dividend—
Analyst Ratings
Company Info
CEORichard Jon Barry
Employees30
SectorHealthcare
IndustryBiotechnology
IPO Date2000-07-14
Websitecassavasciences.com
7801 North Capital of Texas Highway
Austin, TX 78731
US
Austin, TX 78731
US
512 501 2444
About Cassava Sciences, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Anderson Robert Euge | P-Purchase | 8,600 | $2.90 | 2025-11-24 |
| Barry Richard | P-Purchase | 150,000 | $2.76 | 2025-11-20 |
| Barry Richard | P-Purchase | 73,385 | $2.75 | 2025-11-19 |
| Bir Dawn Carter | A-Award | 53,000 | $3.98 | 2025-10-21 |
| Bir Dawn Carter | 0 | — | 2025-10-21 |